The Latest Breaking News from Pfizer

Amid healthcare’s enduring importance and increasing demand for its products and services, here are five dividend-paying healthcare stocks to consider now.

Moderna stock toppled Friday after the FDA delayed an approval decision on its RSV vaccine until the end of the month.

Amid increasing healthcare spending, breakthroughs in genomics and personalized medicine, and the adoption of new technologies, the pharma industry is booming. So, let’s analyze Eli Lilly (LLY) and Pfizer (PFE) to determine which pharma stock will surge from their first-quarter earnings. Read on to find out.

Moderna stock broke out for the first time in a year Thursday after beating first-quarter expectations as its second potential approval looms.

Much lower sales of Covid-19 vaccine Comirnaty and therapeutic Paxlovid accounted for a 20 percent drop in first-quarter revenues to $14.9 billion compared with the year-ago period.

Pfizer stock surged Wednesday after the pharma giant walloped analysts' first-quarter earnings forecast and hiked its guidance.

Pfizer reported a drop in profits on lower sales of Covid-19 related profits Wednesday as it steers investments to other pharmaceutical areas and implements previously announced cost cuts.

June S&P 500 E-Mini futures (ESM24) are down -0.42%, and June Nasdaq 100 E-Mini futures (NQM24) are down -0.73% this morning as mixed earnings and the prospect of higher-for-longer U.S. interest rates weighed on sentiment, with all eyes on the Federal Reserve’s interest rate decision due later in the day.

June S&P 500 E-Mini futures (ESM24) are down -0.29%, and June Nasdaq 100 E-Mini futures (NQM24) are down -0.58% this morning as the prospect of higher-for-longer U.S. interest rates continued to weigh on sentiment, with all eyes on the Federal Reserve’s interest rate decision due later in the day.